2022
DOI: 10.1016/j.xinn.2022.100239
|View full text |Cite
|
Sign up to set email alerts
|

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 48 publications
0
3
0
Order By: Relevance
“…In a randomized phase II clinical study, icotinib plus radiotherapy was compared with radiotherapy alone in older ESCC patients with unresectable tumors: icotinib plus radiotherapy improved the median overall survival compared with radiotherapy alone [64]. Lu et al recently reported the results of a randomized phase II clinical study evaluating the effect of adding cetuximab to paclitaxel-cisplatin chemotherapy compared with chemotherapy alone in ESCC patients with metastatic disease not previously treated; in the whole population of treated ESCC patients, the mPFS was 5.7 months for cetuximab + chemotherapy compared with 4.2 months for chemotherapy alone; in the selected population of ESCC patients with EGFR amplification, the mPFS was 5.45 months for cetuximab + chemotherapy compared with 2.99 months for chemotherapy alone [66]. However, the overall survival was not significantly different in the two treatment arms in the whole ESCC population (11.5 months in the chemotherapy + cetuximab group compared with 10.5 months in the chemotherapy alone group); however, a clear trend of overall survival was observed considering only the EGFR-amplified patients (17.1 months versus 6 months in the cetuximab + chemotherapy and chemotherapy alone, respectively) [66].…”
Section: Egfrmentioning
confidence: 99%
“…In a randomized phase II clinical study, icotinib plus radiotherapy was compared with radiotherapy alone in older ESCC patients with unresectable tumors: icotinib plus radiotherapy improved the median overall survival compared with radiotherapy alone [64]. Lu et al recently reported the results of a randomized phase II clinical study evaluating the effect of adding cetuximab to paclitaxel-cisplatin chemotherapy compared with chemotherapy alone in ESCC patients with metastatic disease not previously treated; in the whole population of treated ESCC patients, the mPFS was 5.7 months for cetuximab + chemotherapy compared with 4.2 months for chemotherapy alone; in the selected population of ESCC patients with EGFR amplification, the mPFS was 5.45 months for cetuximab + chemotherapy compared with 2.99 months for chemotherapy alone [66]. However, the overall survival was not significantly different in the two treatment arms in the whole ESCC population (11.5 months in the chemotherapy + cetuximab group compared with 10.5 months in the chemotherapy alone group); however, a clear trend of overall survival was observed considering only the EGFR-amplified patients (17.1 months versus 6 months in the cetuximab + chemotherapy and chemotherapy alone, respectively) [66].…”
Section: Egfrmentioning
confidence: 99%
“…Moreover, another randomized, multicentre phase II trial used cetuximab in combination with PTX‐cisplatin chemotherapy (CTP) as a first‐line treatment to achieve effective targeted therapy in patients with metastatic ESCC, which significantly prolonged the PFS and mOS of patients and achieved a manageable safety profile. [ 188 ] Another anti‐EGFR monoclonal antibody, nimotuzumab, was administered in combination with chemotherapy in the treatment of locally advanced or metastatic EC and showed a better short‐term effect without accumulation of toxicity and was well tolerated. [ 189 ] EGFR tyrosine kinase inhibitors, such as icotinib and gefitinib, also exhibited significant efficacy in the treatment of patients with EGFR‐overexpressing ESCC.…”
Section: Oesophageal Squamous Carcinoma Therapymentioning
confidence: 99%
“…Positive rates Agents Outcomes EGFR pathways 97%, [62] 49.2% [63] Cetuximab mOS: 9.5 months; [ 187] mOS: 11.5 months. [ 188] Nimotuzumab Disease control rate: 81%. [ 189] mPFS: 13.9 months; mOS: 9 months.…”
Section: Targetsmentioning
confidence: 99%